Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies

被引:26
|
作者
Aiebchun, Thitinan [1 ]
Mahalapbutr, Panupong [2 ]
Auepattanapong, Atima [3 ,4 ]
Khaikate, Onnicha [3 ,4 ]
Seetaha, Supaphorn [5 ]
Tabtimmai, Lueacha [6 ]
Kuhakarn, Chutima [3 ,4 ]
Choowongkomon, Kiattawee [5 ]
Rungrotmongkol, Thanyada [1 ,7 ]
机构
[1] Chulalongkorn Univ, Fac Sci, Dept Biochem, Biocatalyst & Environm Biotechnol Res Unit, Bangkok 10330, Thailand
[2] Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen 40002, Thailand
[3] Mahidol Univ, Fac Sci, Dept Chem, Bangkok 10700, Thailand
[4] Mahidol Univ, Fac Sci, Ctr Excellence Innovat Chem PERCH CIC, Bangkok 10700, Thailand
[5] Kasetsart Univ, Fac Sci, Dept Biochem, Bangkok 10900, Thailand
[6] King Mongkuts Univ Technol North Bangkok, Fac Appl Sci, Dept Biotechnol, Bangkok 10800, Thailand
[7] Chulalongkorn Univ, Fac Sci, Program Bioinformat & Computat Biol, Bangkok 10330, Thailand
来源
MOLECULES | 2021年 / 26卷 / 08期
关键词
EGFR tyrosine kinase; vinyl sulfone derivatives; in silico study; kinase assay; cytotoxicity assay; EPIDERMAL-GROWTH-FACTOR; CELL LUNG-CANCER; MOLECULAR-DYNAMICS; FACTOR RECEPTOR; DECARBOXYLATIVE SULFONYLATION; ERLOTINIB RESISTANCE; POINT MUTATIONS; GEFITINIB; COMPLEX; ACIDS;
D O I
10.3390/molecules26082211
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Epidermal growth factor receptor (EGFR), overexpressed in many types of cancer, has been proved as a high potential target for targeted cancer therapy due to its role in regulating proliferation and survival of cancer cells. In the present study, a series of designed vinyl sulfone derivatives was screened against EGFR tyrosine kinase (EGFR-TK) using in silico and in vitro studies. The molecular docking results suggested that, among 78 vinyl sulfones, there were eight compounds that could interact well with the EGFR-TK at the ATP-binding site. Afterwards, these screened compounds were tested for the inhibitory activity towards EGFR-TK using ADP-Glo (TM) kinase assay, and we found that only VF16 compound exhibited promising inhibitory activity against EGFR-TK with the IC50 value of 7.85 +/- 0.88 nM. In addition, VF16 showed a high cytotoxicity with IC50 values of 33.52 +/- 2.57, 54.63 +/- 0.09, and 30.38 +/- 1.37 mu M against the A431, A549, and H1975 cancer cell lines, respectively. From 500-ns MD simulation, the structural stability of VF16 in complex with EGFR-TK was quite stable, suggesting that this compound could be a novel small molecule inhibitor targeting EGFR-TK.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies
    Kiriwan, Duangnapa
    Seetaha, Supaphorn
    Jiwacharoenchai, Nattanan
    Tabtimmai, Lueacha
    Sousa, Sergio F.
    Songtawee, Napat
    Choowongkomon, Kiattawee
    CHEMICAL BIOLOGY & DRUG DESIGN, 2022, 99 (03) : 456 - 469
  • [2] In silico identification of novel chemical scaffolds as inhibitors of EGFR tyrosine kinase activity
    Cavasotto, Claudio N.
    Ortiz, Maria A.
    Abagyan, R.
    Piedrafita, F. Javier
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [3] Effects of EGFR Tyrosine Kinase Inhibitor Erlotinib in Prostate Cancer Cells In Vitro
    Festuccia, Claudio
    Gravina, Giovanni Luca
    Biordi, Leda
    D'Ascenzo, Sandra
    Dolo, Vincenza
    Ficorella, Corrado
    Ricevuto, Enrico
    Tombolini, Vincenzo
    PROSTATE, 2009, 69 (14): : 1529 - 1537
  • [4] Targeting EGFR tyrosine kinase: Synthesis, in vitro antitumor evaluation, and molecular modeling studies of benzothiazole-based derivatives
    Mokhtar, Amal M.
    El-Messery, Shahenda M.
    Ghaly, Mariam A.
    Hassan, Ghada S.
    BIOORGANIC CHEMISTRY, 2020, 104
  • [5] Skin problems and EGFR-tyrosine kinase inhibitor
    Kozuki, Toshiyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (04) : 291 - 298
  • [6] Identification of a Novel Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase: In Vitro and In Silico Studies
    de Almeida, Raquel B. M.
    Barbosa, Deyse B. B.
    do Bomfim, Mayra R. R.
    Amparo, Jessika A. O.
    Andrade, Bruno S. S.
    Costa, Silvia L. L.
    Campos, Joaquin M.
    Cruz, Jorddy N.
    Santos, Cleydson B. R.
    Leite, Franco H. A.
    Botura, Mariana B. B.
    PHARMACEUTICALS, 2023, 16 (01)
  • [7] 2D QSAR Studies on a Series of Quinazoline Derivatives as Tyrosine Kinase (EGFR) Inhibitor: An Approach to Design Anticancer Agents
    Noolvi, Malleshappa N.
    Patel, Harun M.
    LETTERS IN DRUG DESIGN & DISCOVERY, 2010, 7 (08) : 556 - 586
  • [8] Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia
    Lindhagen, Elin
    Eriksson, Anna
    Wickstrom, Malin
    Danielsson, Katarina
    Grundmark, Birgitta
    Henriksson, Roger
    Nygren, Peter
    Aleskog, Anna
    Larsson, Rolf
    Hoglund, Martin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 81 (05) : 344 - 353
  • [9] Identification of 20(S)-Ginsenoside Rh2 as a Potential EGFR Tyrosine Kinase Inhibitor
    Liang, Yuan
    Zhao, Jingqi
    Zou, Haoyang
    Zhang, Jie
    Zhang, Tiehua
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [10] Metabolism of the Tyrosine Kinase Inhibitor Masitinib In Vitro
    Latham, Bethany
    Jackson, Klarissa
    Vergne, Matthew J.
    FASEB JOURNAL, 2022, 36